Funding Details
- Awarder
- Inbox
- Date Award
- March 26, 2025
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
Company Info
- Traction
- Epicrispr plans to start a Phase 1 trial in New Zealand this year.
- Company Description
- Epicrispr Biotechnologies is developing a first-of-its-kind genetic medicine for facioscapulohumeral muscular dystrophy (FSHD) using CRISPR tools to silence a gene involved in the disease's progression.
- Market
- Rare neuromuscular disorders
- Location
-
San Francisco Bay Area,
California,
USA
- Coinvestors
- Ally Bridge Group, Solve FSHD
Links